Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
20/05/2024 | 12:28 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NYSE:MRK | Merck and Co Inc |
16/05/2024 | 22:15 | Edgar (US Regulatory) | Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses | NYSE:MRK | Merck and Co Inc |
15/05/2024 | 17:31 | Edgar (US Regulatory) | Form POSASR - Post-effective Amendment to an automatic shelf registration statement | NYSE:MRK | Merck and Co Inc |
15/05/2024 | 12:45 | Business Wire | Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline | NYSE:MRK | Merck and Co Inc |
13/05/2024 | 12:45 | Business Wire | Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma | NYSE:MRK | Merck and Co Inc |
09/05/2024 | 13:05 | PR Newswire (Canada) | Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy | NYSE:MRK | Merck and Co Inc |
09/05/2024 | 13:05 | PR Newswire (Canada) | Santé Canada approuve KEYTRUDA® pour le traitement, en association avec une chimiothérapie à base de gemcitabine, des adultes atteints d'un carcinome des voies biliaires non résécable localement avancé ou métastatique | NYSE:MRK | Merck and Co Inc |
09/05/2024 | 12:45 | Business Wire | Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent | NYSE:MRK | Merck and Co Inc |
08/05/2024 | 12:45 | Business Wire | Merck to Participate in the Bank of America Securities 2024 Healthcare Conference | NYSE:MRK | Merck and Co Inc |
06/05/2024 | 22:29 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:MRK | Merck and Co Inc |
06/05/2024 | 22:10 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:MRK | Merck and Co Inc |
01/05/2024 | 13:15 | Business Wire | Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NYSE:MRK | Merck and Co Inc |
29/04/2024 | 15:00 | Business Wire | Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults | NYSE:MRK | Merck and Co Inc |
25/04/2024 | 22:40 | IH Market News | U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower | NYSE:MRK | Merck and Co Inc |
25/04/2024 | 15:09 | IH Market News | Futures Pointing To Sharply Lower Open On Wall Street | NYSE:MRK | Merck and Co Inc |
25/04/2024 | 13:52 | IH Market News | Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings | NYSE:MRK | Merck and Co Inc |
25/04/2024 | 12:30 | Business Wire | Merck Announces First-Quarter 2024 Financial Results | NYSE:MRK | Merck and Co Inc |
19/04/2024 | 13:04 | PR Newswire (Canada) | Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) H | NYSE:MRK | Merck and Co Inc |
19/04/2024 | 13:04 | PR Newswire (Canada) | Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta | NYSE:MRK | Merck and Co Inc |
10/04/2024 | 13:13 | IH Market News | Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News | NYSE:MRK | Merck and Co Inc |
04/04/2024 | 12:45 | Business Wire | Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer | NYSE:MRK | Merck and Co Inc |
03/04/2024 | 14:00 | Business Wire | REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer | NYSE:MRK | Merck and Co Inc |
01/04/2024 | 12:45 | Business Wire | Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 | NYSE:MRK | Merck and Co Inc |
28/03/2024 | 11:45 | Business Wire | European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults | NYSE:MRK | Merck and Co Inc |
27/03/2024 | 11:54 | IH Market News | GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News | NYSE:MRK | Merck and Co Inc |
26/03/2024 | 23:21 | Business Wire | FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) | NYSE:MRK | Merck and Co Inc |
21/03/2024 | 11:45 | Business Wire | Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer | NYSE:MRK | Merck and Co Inc |
19/03/2024 | 14:00 | Business Wire | Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults | NYSE:MRK | Merck and Co Inc |
15/03/2024 | 21:23 | PR Newswire (US) | FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform | NYSE:MRK | Merck and Co Inc |
15/03/2024 | 11:45 | Business Wire | Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer | NYSE:MRK | Merck and Co Inc |